{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:06:24Z","timestamp":1790399184746,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejpb.2024.114422","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T15:45:21Z","timestamp":1721490321000},"page":"114422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Intraperitoneal administration of doxorubicin-encapsulated Brucea javanica oil nanoemulsion against malignant ascites"],"prefix":"10.1016","volume":"202","author":[{"given":"Jie","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlun","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-4304","authenticated-orcid":false,"given":"Shaozhi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114422_b0005","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.semcancer.2022.04.005","article-title":"Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: current status and future perspectives","volume":"86","author":"Ansari","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejpb.2024.114422_b0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastrointest. Surg."},{"key":"10.1016\/j.ejpb.2024.114422_b0015","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1634\/theoncologist.2015-0076","article-title":"Outpatient intraperitoneal catumaxomab therapy for malignant ascites related to advanced gynecologic neoplasms","volume":"20","author":"Kurbacher","year":"2015","journal-title":"Oncologist."},{"key":"10.1016\/j.ejpb.2024.114422_b0020","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.omto.2021.11.008","article-title":"Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment","volume":"23","author":"Shi","year":"2021","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.ejpb.2024.114422_b0025","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jcmm.12575","article-title":"The impact of inflammatory cells in malignant ascites on small intestinal ICCs\u2019 morphology and function","volume":"19","author":"Li","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejpb.2024.114422_b0030","doi-asserted-by":"crossref","first-page":"1138759","DOI":"10.3389\/fonc.2023.1138759","article-title":"Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies","volume":"13","author":"Han","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114422_b0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jso.25453","article-title":"Palliation of malignant ascites","volume":"120","author":"Hodge","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ejpb.2024.114422_b0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2010.07.016","article-title":"A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites","volume":"79","author":"Barni","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejpb.2024.114422_b0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00262-023-03616-y","article-title":"The complex role of IL-10 in malignant ascites: a review","volume":"73","author":"Huang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejpb.2024.114422_b0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"5","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114422_b0055","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.biopha.2017.04.033","article-title":"Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity","volume":"90","author":"Abushouk","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2024.114422_b0060","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJM200506093522322","article-title":"Cabergoline plus Lanreotide for Ectopic Cushing\u2019s Syndrome","volume":"352","author":"Pivonello","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2024.114422_b0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fonc.2019.00353","article-title":"Nanoformulation of Talazoparib delays tumor progression and ascites formation in a late stage cancer model","volume":"9","author":"Baldwin","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejpb.2024.114422_b0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12072-017-9815-0","article-title":"Management of ascites and hepatorenal syndrome","volume":"12","author":"Piano","year":"2018","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.ejpb.2024.114422_b0075","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/DDDT.S155115","article-title":"The apoptotic effects of Brucea javanica fruit extract against HT29 cells associated with p53 upregulation and inhibition of NF-\u03baB translocation","volume":"12","author":"Bagheri","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejpb.2024.114422_b0080","article-title":"Major constituents from Brucea javanica and their pharmacological actions","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114422_b0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12885-018-4328-3","article-title":"Evaluation of efficacy and safety for Brucea javanica oil emulsion in the control of the malignant pleural effusions via thoracic perfusion","volume":"18","author":"Xiang","year":"2018","journal-title":"BMC Cancer."},{"key":"10.1016\/j.ejpb.2024.114422_b0090","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1208\/s12249-010-9454-4","article-title":"Preparation, safety, pharmacokinetics, and pharmacodynamics of liposomes containing Brucea javanica Oil","volume":"11","author":"Cui","year":"2010","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2024.114422_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111122","article-title":"The anti-hepatocellular carcinoma effect of Brucea javanica oil in ascitic tumor-bearing mice: The detection of brusatol and its role","volume":"134","author":"Wang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2024.114422_b0100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3390\/antiox11061094","article-title":"Effect of Theobroma cacao L. on the efficacy and toxicity of doxorubicin in mice bearing Ehrlich ascites carcinoma","volume":"11","author":"Patil","year":"2022","journal-title":"Antioxidants."},{"key":"10.1016\/j.ejpb.2024.114422_b0105","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.3390\/molecules25225414","article-title":"Medicinal activities and nanomedicine delivery strategies for Brucea javanica oil and its molecular components","volume":"25","author":"Yoon","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.ejpb.2024.114422_b0110","first-page":"CD008792","article-title":"Combination versus sequential single agent chemotherapy for metastatic breast cancer","volume":"12","author":"Dear","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2024.114422_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119334","article-title":"Therapeutic efficacy of thermosensitive Pluronic hydrogel for codelivery of resveratrol microspheres and cisplatin in the treatment of liver cancer ascites","volume":"582","author":"Wen","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114422_b0120","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1080\/10717544.2022.2111480","article-title":"Intraperitoneal administration of thermosensitive hydrogel Co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma","volume":"29","author":"Xiao","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114422_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-013-0264-2","article-title":"Intraperitoneal Chemotherapy from Armstrong to HIPEC: Challenges and Promise","volume":"15","author":"Eskander","year":"2014","journal-title":"Curr. Treat Options Oncol."},{"key":"10.1016\/j.ejpb.2024.114422_b0130","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1166\/jbn.2020.3002","article-title":"Injectable hyaluronic acid hydrogel for the co-delivery of gemcitabine nanoparticles and cisplatin for malignant ascites therapy","volume":"16","author":"Wang","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114422_b0135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2024.114422_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.784164","article-title":"Efficacy and safety of Brucea javanica oil emulsion injection in the treatment of gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.ejpb.2024.114422_b0145","doi-asserted-by":"crossref","first-page":"e23197","DOI":"10.1097\/MD.0000000000023197","article-title":"Efficacy and safety of Brucea javanica oil emulsion for liver cancer","volume":"99","author":"Luo","year":"2020","journal-title":"Medicine (baltimore)."},{"key":"10.1016\/j.ejpb.2024.114422_b0150","doi-asserted-by":"crossref","first-page":"856","DOI":"10.5114\/aoms.2015.53306","article-title":"Suppression of human hepatocellular cancer cell proliferation by Brucea javanica oil-loaded liposomes via induction of apoptosis","volume":"11","author":"Yue","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ejpb.2024.114422_b0155","doi-asserted-by":"crossref","first-page":"84974","DOI":"10.18632\/oncotarget.17761","article-title":"Exploring brusatol as a new anti-pancreatic cancer adjuvant: Biological evaluation and mechanistic studies","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ejpb.2024.114422_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154141","article-title":"Efficacy and safety of Brucea javanica oil emulsion injection as adjuvant therapy for cancer: an overview of systematic reviews and meta-analyses","volume":"102","author":"Chen","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejpb.2024.114422_b0165","first-page":"1447","article-title":"Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells","volume":"41","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejpb.2024.114422_b0170","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/965016","article-title":"Seed oil of Brucea javanica induces apoptotic death of acute myeloid leukemia cells via both the death receptors and the mitochondrial-related pathways","volume":"2011","author":"Zhang","year":"2011","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"10.1016\/j.ejpb.2024.114422_b0175","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00018-005-5565-6","article-title":"Mitochondria and calpains mediate caspase-dependent apoptosis induced by doxycycline in HeLa cells","volume":"63","author":"Wu","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.ejpb.2024.114422_b0180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00441-018-2940-9","article-title":"Leptin protects placental cells from apoptosis induced by acidic stress","volume":"375","author":"P\u00e9rez-P\u00e9rez","year":"2019","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ejpb.2024.114422_b0185","doi-asserted-by":"crossref","first-page":"14068","DOI":"10.1002\/jcp.28096","article-title":"Dexmedetomidine improves acute stress-induced liver injury in rats by regulating MKP-1, inhibiting NF-\u03baB pathway and cell apoptosis","volume":"234","author":"Sha","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.ejpb.2024.114422_b0190","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCRESAHA.123.323346","article-title":"Exercise inhibits doxorubicin-induced cardiotoxicity via regulating B cells","volume":"134","author":"Wang","year":"2024","journal-title":"Circ Res."},{"key":"10.1016\/j.ejpb.2024.114422_b0195","doi-asserted-by":"crossref","first-page":"2303254","DOI":"10.1002\/adfm.202303254","article-title":"Bioactive bacteria\/MOFs hybrids can achieve targeted synergistic chemotherapy and chemodynamic therapy against breast tumors","volume":"33","author":"Li","year":"2023","journal-title":"Adv. Functional Mater."},{"key":"10.1016\/j.ejpb.2024.114422_b0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejpb.2023.11.002","article-title":"Combination nanochemotherapy of brain tumor using polymeric nanoparticles loaded with doxorubicin and paclitaxel: an in vitro and in vivo study","volume":"193","author":"Malekpour","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114422_b0205","doi-asserted-by":"crossref","first-page":"0008","DOI":"10.34133\/bmr.0008","article-title":"Enhanced postsurgical cancer treatment using methacrylated glycol chitosan hydrogel for sustained DNA\/doxorubicin delivery and immunotherapy","volume":"28","author":"Seo","year":"2024","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ejpb.2024.114422_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115096","article-title":"Sequentially degradable hydrogel-microsphere loaded with doxorubicin and pioglitazone synergistically inhibits cancer stemness of osteosarcoma","volume":"165","author":"Cao","year":"2023","journal-title":"Biomed. Pharmacother."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T07:33:33Z","timestamp":1736408013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124002480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":42,"alternative-id":["S0939641124002480"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114422","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal administration of doxorubicin-encapsulated Brucea javanica oil nanoemulsion against malignant ascites","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114422"}}